India Pharma Outlook Team | Monday, 13 October 2025
India's Natco Pharma has stated its intention to buy a substantial proportion of shares of the South African pharmaceutical leader Adcock Ingram.
The value of the transaction is R 4.2 billion, which is a significant milestone in the global expansion strategy of Natco. As a result of the takeover, Adcock Ingram will be a private company, with Bidvest Group and Natco jointly owning it. Bidvest will still be the majority shareholder.
The transaction was highly supported by the overwhelming majority of over 98% of Adcock Ingram shareholders who voted for the proposal of Natco at the shareholder meeting. Subsequently, after the completion of the share purchase, Adcock Ingram will cease trading at the JSE.
Over the years, Adcock Ingram has been the South African pharmaceutical company that has been there for you since 1890. It has built a comprehensive portfolio of prescription medicines, OTC drugs, and hospital products.
The partnership will likely not only stabilize the company operations but also broaden its geographical coverage outside Southern Africa especially in the generics field.
Also Read: Samsung Biologics Launches New ExellenS Manufacturing System
Adcock Ingram's Chief Financial Officer, Dorette Neethling, stated that the support of "a shareholder like Natco who is strong, vertically integrated and has global resources" will be the main driver of portfolio expansion and long-term sustainability.
According to Rajeev Nannapaneni, CEO and Vice Chair of Natco Pharma, "This acquisition will enable us to access the Southern African market in a well-established manner and keep us in touch with the rest of the African continent, thus granting us easy access to affordable medicines and facilitating the expansion of our global footprint."
